Dimer Pharmaceuticals is a cutting-edge biotech company revolutionizing treatments for cancer and neurodegenerative diseases through its innovative “Oncodegenic Approach.” Epidemiological data reveal an inverse relationship between these conditions, presenting a unique therapeutic opportunity to target shared biological pathways and molecular mechanisms. By integrating insights from prion biology and leveraging oncology strategies, Dimer develops therapies addressing the underlying drivers of both diseases. This cross-disciplinary innovation uncovers opportunities often overlooked in traditional single-disease models, enabling groundbreaking solutions for complex conditions. With a patient-centered mission, advanced research, and a commitment to scientific progress, Dimer is dedicated to delivering transformative treatments, improving patient outcomes, and shaping a new frontier in healthcare innovation.